TiNivo-2: Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Sponsor: AVEO Pharmaceuticals, Inc.
Protocol AV-951-20-304: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor
Patients that are eligible to participate in this study will have a renal cell carcinoma with a clear cell component that has been treated with 1-2 lines of therapy including an immune checkpoint inhibitor in the metastatic setting.
Participants will be randomized 1:1 to receive either tivozanib as a single agent or in combination with nivolumab.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.